WORLDWIDE

Oral Arsenic Formulation for Treatment of Acute Promyelocytic Leukaemia (APL)

Australian pharmaceutical manufacturer Phebra, is pleased to announce its development of an innovative oral arsenic trioxide formulation for the treatment of APL.